BCL2L12 and acute myeloid leukemia: As they have been proven to be potent targets in the treatment of AML, we examined the silencing of both BCL2L12 and survivin and showed how it leads to the decrease in proliferation of the KG1 and KG1a leukemic stem cell models at different time points.